NBIX
Neurocrine Biosciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website neurocrine.com
- Employees(FY) 1400
- ISIN US64125C1099
Performance
+3.83%
1W
+7.73%
1M
-21.29%
3M
-14.34%
6M
-8.52%
YTD
+5.72%
1Y
Profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Technical Analysis of NBIX 2024-11-04
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-04 08:30
- 2024-11-04 08:25
- 2024-11-03 19:30
- 2024-11-03 19:25
- 2024-10-31 03:04
- 2024-10-31 01:09
- 2024-10-30 09:30
- 2024-10-30 08:10
- 2024-10-30 07:42
- 2024-10-30 07:07
Neurocrine: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-10-30 07:00
- 2024-10-29 19:00
- 2024-10-23 10:56
- 2024-10-23 10:01
- 2024-10-17 13:02
- 2024-10-16 16:04
- 2024-10-11 10:02
Exploring Three High Growth Tech Stocks in the United States(Simply Wall St.)
- 2024-10-09 16:01
- 2024-10-09 04:01
- 2024-10-08 20:00
NBIX: Lowering target price to $117.00(Argus Research)
- 2024-10-04 06:45
- 2024-10-03 06:15
- 2024-09-30 08:30
- 2024-09-29 20:30
- 2024-09-19 16:01
- 2024-09-19 04:01
- 2024-09-16 11:05
- 2024-09-14 19:25
- 2024-09-13 04:32
Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint(Clinical Trials Arena)
- 2024-09-12 17:10
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.